Humanwell subsidiary drug application accepted by Chinese regulators

Humanwell Healthcare Group Co., Ltd. announced that its controlled subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., recently received acceptance from the National Medical Products Administration for its drug marketing authorization applications for Dextroamphetamine Mesylate Capsules. The drug is classified as a Class 3 chemical medicine for domestic production.

The Dextroamphetamine Mesylate Capsules, originally approved in the United States, are intended for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 years and older. Yichang Humanwell's current application focuses on ADHD for adults and children aged 6 years and above.

Currently, there are no other Dextroamphetamine Mesylate Capsule products approved for market or imported into China. Yichang Humanwell has invested approximately yuan 90 million in the research and development of this project. The company anticipates that a successful review and approval will enrich its product line and enhance its market competitiveness.